Codrituzumab Biosimilar - Research Grade

Human

GPC3

>1mg/ml

Human IgG1

https://www.imgt.org/mAb-DB/

ICH3002

P51654

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of codrituzumab, a humanized IgG1 monoclonal antibody directed against Glypican-3 (GPC3). It is supplied strictly for research use only and is not the clinical drug; it is not intended for human or veterinary use. Built as a human IgG1 targeting human GPC3, the reagent reproduces the antigen-binding specificity of the originator, making it useful as a defined tool for interrogating GPC3 biology in vitro. Typical research applications include serving as a benchmark or reference binder in assays comparing anti-GPC3 candidates, as a positive control in binding and neutralization work, and as a scaffold for ADCC-focused or antibody-drug-conjugate development studies. The material is offered at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options) and is available in bulk milligram-to-gram quantities to support assay standardization, preclinical model work, and lot-to-lot comparability. Because it carries a native, unconjugated human IgG1 Fc, it also supports Fc-effector-function studies alongside its antigen-recognition role. Glypican-3 (GPC3) is a member of the glypican family of heparan sulfate proteoglycans, attached to the outer cell membrane via a glycosylphosphatidylinositol (GPI) anchor. The core protein is cleaved by furin into two subunits held together by a disulfide bond, and it bears heparan sulfate chains near its C-terminus. GPC3 modulates several developmental signaling pathways, including Wnt, Hedgehog, FGF and BMP, thereby influencing cell growth and morphogenesis during embryogenesis. Loss-of-function mutations cause Simpson-Golabi-Behmel overgrowth syndrome. In adults GPC3 is largely silenced in most normal tissues but is markedly re-expressed in hepatocellular carcinoma and certain other tumors, which underpins its interest as a tumor-associated antigen and diagnostic marker. This restricted, oncofetal expression pattern makes GPC3 an attractive target for antibody-based research.

GTR2-2, Intestinal protein OCI-5, MXR7, Glypican-3, OCI5

Detects human GPC3. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Codrituzumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Codrituzumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Codrituzumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Codrituzumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Codrituzumab that binds human GPC3.